{"entity":{"id":"da-tech-apoe-testing","kind":"technology","name":"ApoE testing","aka":[],"tldr":"ApoE ε4 is a risk variant used in antibody-safety counselling. It does not diagnose Alzheimer’s disease.","summary":"US labels for amyloid antibodies discuss ApoE ε4 and ARIA risk. Testing needs consent and counselling, not a casual consumer kit used as a diagnosis.","asOf":"2026-09-21","links":[{"label":"FDA Leqembi","url":"https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":["da-front-genetics"],"technologies":[],"targets":[],"drugs":["da-lecanemab","da-donanemab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Genotyping APOE alleles, especially ε4, to inform ARIA risk discussions.","strengths":[],"limitations":[]},"route":"/technologies/da-tech-apoe-testing/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}],"section":[{"id":"da-front-genetics","kind":"section","name":"Genetics","route":"/fronts/da-front-genetics/"}],"drug":[{"id":"da-donanemab","kind":"drug","name":"Donanemab","route":"/drugs/da-donanemab/"},{"id":"da-lecanemab","kind":"drug","name":"Lecanemab","route":"/drugs/da-lecanemab/"}]}}